81 FR 44034 - Government-Owned Inventions; Availability for Licensing
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health Federal Register Volume 81, Issue 129 (July 6, 2016)
National Institutes of Health
Federal Register Volume 81, Issue 129 (July 6, 2016)
| Page Range | 44034-44034 | |
| FR Document | 2016-15890 |
[Federal Register Volume 81, Number 129 (Wednesday, July 6, 2016)] [Notices] [Page 44034] From the Federal Register Online [www.thefederalregister.org] [FR Doc No: 2016-15890] [[Page 44034]] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Inventions; Availability for Licensing AGENCY: National Institutes of Health, HHS. ACTION: Notice. ----------------------------------------------------------------------- SUMMARY: The invention listed below is owned by an agency of the U.S. Government and is available for licensing in the U.S. in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing. ADDRESSES: Invention Development and Marketing Unit, Technology Transfer Center, National Cancer Institute, 9609 Medical Center Drive, Mail Stop 9702, Rockville, MD 20850-9702. FOR FURTHER INFORMATION CONTACT: Information on licensing, and copies of the U.S. patent applications listed below may be obtained by contacting: Attn. Invention Development and Marketing Unit, Technology Transfer Center, National Cancer Institute, 9609 Medical Center Drive, Mail Stop 9702, Rockville, MD 20850-9702, Tel. 240-276-5515 or email [email protected]. A signed Confidential Disclosure Agreement may be required to receive copies of the patent applications. SUPPLEMENTARY INFORMATION: Technology description follows. Title of Invention: Improved Fixative for Paraffin-Embedded Tissue Samples. Description of Technology Tissues samples collected during medical procedures, such as biopsies, are used to diagnose a wide variety of diseases. Before diagnosis, patient samples are typically processed by fixation and paraffin embedding. This fixation/embedding process is used to preserve tissue morphology and histology for subsequent evaluation. Unfortunately, most fixative agents damage or destroy nucleic acids (RNA and DNA) and proteins, thereby potentially impairing diagnostic assessment of tissue. Researchers in the National Cancer Institute's Laboratory of Pathology have developed an improved tissue fixative solution that is formaldehyde-free. This fixative, BE70, significantly improves DNA, RNA, and protein biomolecule integrity in histological samples compared to traditional fixatives. Additionally, BE70 is compatible with current protocols and does not alter tissue processing. In vitro an in vivo data are available and the fixative has been tested on paraffin- embedded samples. Potential Commercial ApplicationsImproves integrity of fixed tissue samples. Improves RNA/DNA quality in fixed tissue samples. Non-cross linking, improves protein quality. Value Proposition There is substantial interest in new fixatives to replace neutral buffered formalin (a carcinogen) as primary fixative agent for surgical pathology. BE70 overcomes several limitations of other fixatives, including cost and disposal issues. Could be formulated as a concentrate, and marketed as an additive (to be added during dilution of ethanol). Development Stage In vivo data: YES. Inventor(s) Stephen M. Hewitt (NCI), Joon-Yong Chung (NCI), Candice D. Perry (Leidos Biomedical LLC). Intellectual Property HHS Reference No. E-139-2015/0-US-01 US Provisional Patent Application 62/255,030 (HHS Reference No. E-139-2015/0-US-01) filed November 13, 2015, entitled ``Fixative and Methods of Use''. Publications Perry C, Chung JY, et al. J Histochem Cytochem. 2016 May 24; E-pub [PMID: 27221702]. Contact Information Requests for copies of the patent application or inquiries about licensing, research collaborations, and co-development opportunities should be sent to John D. Hewes, Ph.D., email: [email protected]. Dated: June 28, 2016. John D. Hewes, Technology Transfer Specialist, Technology Transfer Center, National Cancer Institute. [FR Doc. 2016-15890 Filed 7-5-16; 8:45 am] BILLING CODE 4140-01-P
![44034 Federal Register / Vol. 81, No. 129 / Wednesday, July 6, 2016 / Notices
DEPARTMENT OF HEALTH AND compared to traditional fixatives. DEPARTMENT OF HEALTH AND
HUMAN SERVICES Additionally, BE70 is compatible with HUMAN SERVICES
current protocols and does not alter
National Institutes of Health tissue processing. In vitro an in vivo National Institutes of Health
data are available and the fixative has
Government-Owned Inventions; National Institute on Aging; Notice of
been tested on paraffin-embedded
Availability for Licensing Closed Meeting
samples.
AGENCY: National Institutes of Health, Pursuant to section 10(d) of the
Potential Commercial Applications Federal Advisory Committee Act, as
HHS.
ACTION: Notice. • Improves integrity of fixed tissue amended (5 U.S.C. App.), notice is
samples. hereby given of the following meeting.
SUMMARY: The invention listed below is The meeting will be closed to the
owned by an agency of the U.S. • Improves RNA/DNA quality in public in accordance with the
Government and is available for fixed tissue samples. provisions set forth in sections
licensing in the U.S. in accordance with • Non-cross linking, improves protein 552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
35 U.S.C. 209 and 37 CFR part 404 to quality. as amended. The grant applications and
achieve expeditious commercialization the discussions could disclose
of results of federally-funded research Value Proposition confidential trade secrets or commercial
and development. Foreign patent property such as patentable material,
• There is substantial interest in new
applications are filed on selected and personal information concerning
fixatives to replace neutral buffered
inventions to extend market coverage individuals associated with the grant
formalin (a carcinogen) as primary
for companies and may also be available applications, the disclosure of which
fixative agent for surgical pathology.
for licensing. would constitute a clearly unwarranted
ADDRESSES: Invention Development and • BE70 overcomes several limitations invasion of personal privacy.
Marketing Unit, Technology Transfer of other fixatives, including cost and
Name of Committee: National Institute on
Center, National Cancer Institute, 9609 disposal issues. Aging Special Emphasis Panel; Delirium
Medical Center Drive, Mail Stop 9702, • Could be formulated as a Research Networks.
Rockville, MD 20850–9702. concentrate, and marketed as an Date: July 29, 2016.
FOR FURTHER INFORMATION CONTACT: additive (to be added during dilution of Time: 2:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
Information on licensing, and copies of ethanol). applications.
the U.S. patent applications listed below Place: National Institute on Aging,
may be obtained by contacting: Attn. Development Stage
Gateway Building, Suite 2W200, 7201
Invention Development and Marketing In vivo data: YES. Wisconsin Avenue, Bethesda, MD 20892,
Unit, Technology Transfer Center, (Telephone Conference Call).
National Cancer Institute, 9609 Medical Inventor(s) Contact Person: Isis S. Mikhail, DRPH, MD,
Center Drive, Mail Stop 9702, Rockville, MPH, National Institute on Aging, Gateway
MD 20850–9702, Tel. 240–276–5515 or Stephen M. Hewitt (NCI), Joon-Yong Building, 7201 Wisconsin Avenue, Suite
Chung (NCI), Candice D. Perry (Leidos 2W200, Bethesda, MD 20892, 301–402–7704.
email ncitechtransfer@mail.nih.gov. A
Biomedical LLC). mikhaili@mail.nih.gov.
signed Confidential Disclosure
(Catalogue of Federal Domestic Assistance
Agreement may be required to receive Intellectual Property Program Nos. 93.866, Aging Research,
copies of the patent applications. National Institutes of Health, HHS)
SUPPLEMENTARY INFORMATION: HHS Reference No. E–139–2015/0–
US–01 US Provisional Patent Dated: June 29, 2016.
Technology description follows.
Title of Invention: Improved Fixative Application 62/255,030 (HHS Reference Melanie J. Gray,
for Paraffin-Embedded Tissue Samples. No. E–139–2015/0–US–01) filed Program Analyst, Office of Federal Advisory
November 13, 2015, entitled ‘‘Fixative Committee Policy.
Description of Technology [FR Doc. 2016–15882 Filed 7–5–16; 8:45 am]
and Methods of Use’’.
Tissues samples collected during BILLING CODE 4140–01–P
medical procedures, such as biopsies, Publications
are used to diagnose a wide variety of
Perry C, Chung JY, et al. J Histochem DEPARTMENT OF HEALTH AND
diseases. Before diagnosis, patient
samples are typically processed by Cytochem. 2016 May 24; E-pub [PMID: HUMAN SERVICES
fixation and paraffin embedding. This 27221702].
fixation/embedding process is used to National Institutes of Health
Contact Information
preserve tissue morphology and
Requests for copies of the patent National Institute on Drug Abuse;
histology for subsequent evaluation.
application or inquiries about licensing, Notice of Closed Meeting
Unfortunately, most fixative agents
damage or destroy nucleic acids (RNA research collaborations, and co- Pursuant to section 10(d) of the
and DNA) and proteins, thereby development opportunities should be Federal Advisory Committee Act, as
potentially impairing diagnostic sent to John D. Hewes, Ph.D., email: amended (5 U.S.C. App), notice is
assessment of tissue. john.hewes@nih.gov. hereby given of the following meeting.
ehiers on DSK5VPTVN1PROD with NOTICES
Researchers in the National Cancer Dated: June 28, 2016.
The meeting will be closed to the
Institute’s Laboratory of Pathology have public in accordance with the
developed an improved tissue fixative John D. Hewes, provisions set forth in sections
solution that is formaldehyde-free. This Technology Transfer Specialist, Technology 552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
fixative, BE70, significantly improves Transfer Center, National Cancer Institute. as amended. The grant applications and
DNA, RNA, and protein biomolecule [FR Doc. 2016–15890 Filed 7–5–16; 8:45 am] the discussions could disclose
integrity in histological samples BILLING CODE 4140–01–P confidential trade secrets or commercial
VerDate Sep<11>2014 15:04 Jul 05, 2016 Jkt 238001 PO 00000 Frm 00049 Fmt 4703 Sfmt 4703 E:\FR\FM\06JYN1.SGM 06JYN1](https://thefederalregister.org/doc/81_FR_44163/page/1.svg)
Document Created: 2016-07-06 07:56:14
Document Modified: 2016-07-06 07:56:14
| Category | Regulatory Information | |
| Collection | Federal Register | |
| sudoc Class | AE 2.7: GS 4.107: AE 2.106: | |
| Publisher | Office of the Federal Register, National Archives and Records Administration | |
| Section | Notices | |
| Action | Notice. | |
| Contact | Information on licensing, and copies of the U.S. patent applications listed below may be obtained by contacting: Attn. Invention Development and Marketing Unit, Technology Transfer Center, National Cancer Institute, 9609 Medical Center Drive, Mail Stop 9702, Rockville, MD 20850-9702, Tel. 240-276-5515 or email [email protected] A signed Confidential Disclosure Agreement may be required to receive copies of the patent applications. | |
| FR Citation | 81 FR 44034 |
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR